Shots:
Avista to receive $7.5M up front & will be eligible to receive an additional fee in the research phase, clinical and sales milestones along with royalties with a total deal value of ~$1B
Roche gets the right to license novel capsids & will be responsible to conduct preclinical, clinical, and commercialization activities for gene therapy programs using novel capsids
The collaboration will use Avista’s scAAVengr platform technology to develop IVT AAV capsids for retinal diseases with reduced immunogenicity. The technology uses a high-throughput technique & built-in quantitative validation of novel cell-specific AAVs, facilitating the quick development of gene therapies for clinical use
Ref: Bussinesswire | Image: Roche
